Share Price and Basic Stock Data
Last Updated: October 9, 2025, 12:56 am
| PEG Ratio | 26.88 |
|---|
Analyst Insight & Comprehensive Analysis
Elixir Capital Ltd, a Finance & Investments company, currently trades at ₹132 with a Market Cap of ₹76.8 Cr. The company’s Price-to-Earnings ratio stands at 12.9, Return on Equity at 18.0%, and Return on Capital Employed at 20.1%. Notably, Elixir Capital boasts a healthy Operating Profit Margin of 38.92% and a comfortable Interest Coverage Ratio of 10.26x. With Promoters holding a significant stake of 71.29% and a low Current Ratio of 0.81 days, the firm exhibits strong ownership structure and efficient working capital management. However, the company’s high Borrowings of ₹31.32 Cr and relatively modest Public shareholding of 28.72% pose risks in terms of leverage and limited market float.
Moving forward, Elixir Capital’s robust Reserves of ₹50.97 Cr provide a cushion against economic uncertainties, while enhancing shareholder confidence. To improve its outlook, the company could focus on reducing debt levels and increasing public float to enhance liquidity and market participation. Conversely, a worsening scenario could arise from a significant decline in Net Profit margins or a sudden increase in borrowing costs, impacting profitability and financial stability. In conclusion, investors should monitor Elixir Capital’s leverage levels and operational efficiency closely to navigate potential risks and capitalize on its growth potential within the Finance & Investments sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Elixir Capital Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modern Shares & Stockbrokers Ltd | 12.7 Cr. | 43.5 | 67.7/36.4 | 45.5 | 43.5 | 0.00 % | 3.32 % | 1.74 % | 10.0 |
| Monarch Networth Capital Ltd | 2,462 Cr. | 311 | 495/280 | 15.9 | 102 | 0.32 % | 33.3 % | 26.2 % | 10.0 |
| Monotype India Ltd | 39.4 Cr. | 0.56 | 2.42/0.46 | 3.83 | 0.02 | 0.00 % | 286 % | % | 1.00 |
| Multipurpose Trading & Agencies Ltd | 4.69 Cr. | 9.46 | 13.3/8.25 | 10.3 | 0.00 % | 3.68 % | 3.38 % | 10.0 | |
| Munoth Financial Services Ltd | 29.5 Cr. | 57.5 | 72.0/48.0 | 20.6 | 0.00 % | 2.41 % | 3.38 % | 10.0 | |
| Industry Average | 6,860.57 Cr | 1,444.86 | 137.30 | 3,807.75 | 0.31% | 21.70% | 14.20% | 7.34 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -3.53 | 7.80 | 0.08 | -0.60 | 4.75 | 6.09 | 5.91 | 15.81 | 14.72 | 18.56 | 6.04 | -3.96 | 10.92 |
| Expenses | 1.34 | 1.53 | 1.31 | 1.51 | 1.57 | 1.68 | 1.62 | 2.41 | 3.04 | 3.00 | 3.70 | 5.59 | 6.67 |
| Operating Profit | -4.87 | 6.27 | -1.23 | -2.11 | 3.18 | 4.41 | 4.29 | 13.40 | 11.68 | 15.56 | 2.34 | -9.55 | 4.25 |
| OPM % | 80.38% | -1,537.50% | 66.95% | 72.41% | 72.59% | 84.76% | 79.35% | 83.84% | 38.74% | 38.92% | |||
| Other Income | 0.28 | 0.05 | 0.17 | 0.24 | 0.34 | 0.89 | 0.22 | 1.20 | 0.27 | 0.16 | 0.22 | -0.13 | 1.17 |
| Interest | 0.22 | 0.28 | 0.33 | 0.30 | 0.34 | 0.40 | 0.33 | 0.45 | 0.43 | 0.56 | 0.66 | 0.38 | 0.62 |
| Depreciation | 0.07 | 0.08 | 0.08 | 0.10 | 0.08 | 0.09 | 0.08 | 0.09 | 0.07 | 0.09 | 0.08 | 0.26 | 0.11 |
| Profit before tax | -4.88 | 5.96 | -1.47 | -2.27 | 3.10 | 4.81 | 4.10 | 14.06 | 11.45 | 15.07 | 1.82 | -10.32 | 4.69 |
| Tax % | 1.43% | 6.04% | -2.72% | 16.74% | 1.61% | 15.38% | 22.44% | 24.32% | 24.98% | 25.08% | 34.62% | -18.22% | 21.54% |
| Net Profit | -4.95 | 5.61 | -1.43 | -2.65 | 3.06 | 4.08 | 3.19 | 10.63 | 8.59 | 11.30 | 1.19 | -8.44 | 3.69 |
| EPS in Rs | -8.53 | 28.98 | -1.77 | -3.38 | 3.89 | 5.39 | 4.07 | 13.54 | 10.94 | 14.41 | 1.52 | -10.80 | 4.70 |
Last Updated: August 19, 2025, 3:48 pm
Below is a detailed analysis of the quarterly data for Elixir Capital Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 10.92 Cr.. The value appears strong and on an upward trend. It has increased from -3.96 Cr. (Mar 2025) to 10.92 Cr., marking an increase of 14.88 Cr..
- For Expenses, as of Jun 2025, the value is 6.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.59 Cr. (Mar 2025) to 6.67 Cr., marking an increase of 1.08 Cr..
- For Operating Profit, as of Jun 2025, the value is 4.25 Cr.. The value appears strong and on an upward trend. It has increased from -9.55 Cr. (Mar 2025) to 4.25 Cr., marking an increase of 13.80 Cr..
- For OPM %, as of Jun 2025, the value is 38.92%. The value appears strong and on an upward trend. It has increased from 0.00% (Mar 2025) to 38.92%, marking an increase of 38.92%.
- For Other Income, as of Jun 2025, the value is 1.17 Cr.. The value appears strong and on an upward trend. It has increased from -0.13 Cr. (Mar 2025) to 1.17 Cr., marking an increase of 1.30 Cr..
- For Interest, as of Jun 2025, the value is 0.62 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.38 Cr. (Mar 2025) to 0.62 Cr., marking an increase of 0.24 Cr..
- For Depreciation, as of Jun 2025, the value is 0.11 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.26 Cr. (Mar 2025) to 0.11 Cr., marking a decrease of 0.15 Cr..
- For Profit before tax, as of Jun 2025, the value is 4.69 Cr.. The value appears strong and on an upward trend. It has increased from -10.32 Cr. (Mar 2025) to 4.69 Cr., marking an increase of 15.01 Cr..
- For Tax %, as of Jun 2025, the value is 21.54%. The value appears to be increasing, which may not be favorable. It has increased from -18.22% (Mar 2025) to 21.54%, marking an increase of 39.76%.
- For Net Profit, as of Jun 2025, the value is 3.69 Cr.. The value appears strong and on an upward trend. It has increased from -8.44 Cr. (Mar 2025) to 3.69 Cr., marking an increase of 12.13 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.70. The value appears strong and on an upward trend. It has increased from -10.80 (Mar 2025) to 4.70, marking an increase of 15.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: July 22, 2025, 2:05 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 12 | 4 | 12 | 10 | 4 | -0 | 20 | 25 | 4 | 35 | 35 |
| Expenses | 2 | 2 | 2 | 3 | 4 | 3 | 4 | 5 | 6 | 6 | 7 | 15 |
| Operating Profit | 2 | 10 | 2 | 10 | 6 | 0 | -4 | 15 | 19 | -1 | 27 | 20 |
| OPM % | 56% | 85% | 49% | 79% | 63% | 9% | 76% | 77% | -32% | 79% | 57% | |
| Other Income | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 9 | 3 | 9 | 6 | -0 | -5 | 14 | 17 | -3 | 26 | 18 |
| Tax % | 30% | 29% | 24% | 25% | 28% | -10% | 10% | 11% | 24% | 28% | 20% | 30% |
| Net Profit | 1 | 7 | 2 | 7 | 4 | -0 | -4 | 12 | 13 | -3 | 21 | 13 |
| EPS in Rs | 1.40 | 8.43 | 2.89 | 11.89 | 5.36 | -0.36 | -6.60 | 15.72 | 16.54 | -5.91 | 36.12 | 16.08 |
| Dividend Payout % | 121% | 20% | 12% | 11% | 23% | -345% | -19% | 8% | 8% | -21% | 3% | 8% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 600.00% | -71.43% | 250.00% | -42.86% | -100.00% | 400.00% | 8.33% | -123.08% | 800.00% | -38.10% |
| Change in YoY Net Profit Growth (%) | 0.00% | -671.43% | 321.43% | -292.86% | -57.14% | 500.00% | -391.67% | -131.41% | 923.08% | -838.10% |
Elixir Capital Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | % |
| 3 Years: | 14% |
| TTM: | -26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 35% |
| 3 Years: | 0% |
| TTM: | -69% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | 39% |
| 1 Year: | -11% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 21% |
| 3 Years: | 17% |
| Last Year: | 18% |
Last Updated: September 5, 2025, 3:21 pm
Balance Sheet
Last Updated: September 10, 2025, 3:35 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.78 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 |
| Reserves | 9.70 | 13.44 | 13.93 | 17.63 | 21.16 | 19.76 | 14.71 | 22.83 | 31.44 | 28.01 | 42.63 | 50.97 |
| Borrowings | 1.54 | 0.57 | 1.95 | 1.72 | 1.59 | 1.22 | 1.24 | 17.44 | 17.68 | 7.34 | 23.60 | 31.32 |
| Other Liabilities | 6.73 | 8.54 | 8.39 | 11.22 | 11.68 | 11.71 | 16.75 | 26.76 | 27.72 | 26.38 | 24.36 | 27.50 |
| Total Liabilities | 23.75 | 28.35 | 30.07 | 36.37 | 40.23 | 38.49 | 38.50 | 72.83 | 82.64 | 67.53 | 96.39 | 115.59 |
| Fixed Assets | 5.84 | 5.67 | 5.30 | 4.75 | 4.87 | 4.54 | 4.20 | 3.93 | 3.69 | 3.54 | 3.26 | 3.64 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.19 | 0.71 | 0.83 | 0.00 | 0.00 | 0.00 | 9.91 | 12.51 | 11.93 | 11.07 | 12.24 | 17.96 |
| Other Assets | 16.72 | 21.97 | 23.94 | 31.62 | 35.36 | 33.95 | 24.39 | 56.39 | 67.02 | 52.92 | 80.89 | 93.99 |
| Total Assets | 23.75 | 28.35 | 30.07 | 36.37 | 40.23 | 38.49 | 38.50 | 72.83 | 82.64 | 67.53 | 96.39 | 115.59 |
Below is a detailed analysis of the balance sheet data for Elixir Capital Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 5.80 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.80 Cr..
- For Reserves, as of Mar 2025, the value is 50.97 Cr.. The value appears strong and on an upward trend. It has increased from 42.63 Cr. (Mar 2024) to 50.97 Cr., marking an increase of 8.34 Cr..
- For Borrowings, as of Mar 2025, the value is 31.32 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 23.60 Cr. (Mar 2024) to 31.32 Cr., marking an increase of 7.72 Cr..
- For Other Liabilities, as of Mar 2025, the value is 27.50 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 24.36 Cr. (Mar 2024) to 27.50 Cr., marking an increase of 3.14 Cr..
- For Total Liabilities, as of Mar 2025, the value is 115.59 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 96.39 Cr. (Mar 2024) to 115.59 Cr., marking an increase of 19.20 Cr..
- For Fixed Assets, as of Mar 2025, the value is 3.64 Cr.. The value appears strong and on an upward trend. It has increased from 3.26 Cr. (Mar 2024) to 3.64 Cr., marking an increase of 0.38 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 17.96 Cr.. The value appears strong and on an upward trend. It has increased from 12.24 Cr. (Mar 2024) to 17.96 Cr., marking an increase of 5.72 Cr..
- For Other Assets, as of Mar 2025, the value is 93.99 Cr.. The value appears strong and on an upward trend. It has increased from 80.89 Cr. (Mar 2024) to 93.99 Cr., marking an increase of 13.10 Cr..
- For Total Assets, as of Mar 2025, the value is 115.59 Cr.. The value appears strong and on an upward trend. It has increased from 96.39 Cr. (Mar 2024) to 115.59 Cr., marking an increase of 19.20 Cr..
Notably, the Reserves (50.97 Cr.) exceed the Borrowings (31.32 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.46 | 9.43 | 0.05 | 8.28 | 4.41 | -1.22 | -5.24 | -2.44 | 1.32 | -8.34 | 3.40 | -11.32 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 8.51 | 0.00 | 0.82 | 3.24 | 5.75 | 1.97 | -2,646.25 | 0.37 | 5.21 | 21.12 | 2.42 | 0.81 |
| Inventory Days | -7,418.62 | |||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 8.51 | 0.00 | 0.82 | 3.24 | 5.75 | 1.97 | -10,064.88 | 0.37 | 5.21 | 21.12 | 2.42 | 0.81 |
| Working Capital Days | 748.91 | 442.37 | 1,232.80 | 648.53 | 929.94 | 2,434.65 | 3,102.50 | 388.25 | 431.07 | 1,684.75 | 598.25 | 697.42 |
| ROCE % | 7.44% | 38.27% | 6.27% | 29.05% | 16.35% | -0.13% | -13.23% | 32.98% | 29.06% | -2.45% | 36.75% | 20.07% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 16.07 | 26.89 | -4.20 | 16.54 | 15.72 |
| Diluted EPS (Rs.) | 16.07 | 26.89 | -4.20 | 16.54 | 15.72 |
| Cash EPS (Rs.) | 22.64 | 36.70 | -5.32 | 23.00 | 21.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 97.83 | 117.55 | 83.14 | 90.74 | 70.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 97.83 | 117.55 | 83.14 | 90.74 | 70.07 |
| Revenue From Operations / Share (Rs.) | 60.94 | 56.07 | 6.48 | 39.92 | 33.12 |
| PBDIT / Share (Rs.) | 35.96 | 47.25 | -2.06 | 32.80 | 25.90 |
| PBIT / Share (Rs.) | 35.10 | 46.67 | -2.64 | 32.17 | 25.19 |
| PBT / Share (Rs.) | 31.06 | 44.94 | -4.59 | 29.30 | 23.55 |
| Net Profit / Share (Rs.) | 21.78 | 36.11 | -5.90 | 22.37 | 21.07 |
| NP After MI And SOA / Share (Rs.) | 16.07 | 26.89 | -4.20 | 16.54 | 15.72 |
| PBDIT Margin (%) | 59.00 | 84.27 | -31.82 | 82.16 | 78.20 |
| PBIT Margin (%) | 57.60 | 83.23 | -40.75 | 80.58 | 76.05 |
| PBT Margin (%) | 50.95 | 80.14 | -70.85 | 73.40 | 71.10 |
| Net Profit Margin (%) | 35.74 | 64.40 | -91.11 | 56.04 | 63.62 |
| NP After MI And SOA Margin (%) | 26.37 | 47.96 | -64.80 | 41.42 | 47.47 |
| Return on Networth / Equity (%) | 16.42 | 32.22 | -7.20 | 25.76 | 31.86 |
| Return on Capital Employeed (%) | 25.50 | 39.68 | -3.17 | 35.43 | 35.89 |
| Return On Assets (%) | 8.06 | 16.19 | -3.60 | 11.61 | 12.52 |
| Total Debt / Equity (X) | 0.55 | 0.48 | 0.21 | 0.47 | 0.60 |
| Asset Turnover Ratio (%) | 0.33 | 0.39 | 0.05 | 0.29 | 0.34 |
| Current Ratio (X) | 2.35 | 2.52 | 2.81 | 2.31 | 1.91 |
| Quick Ratio (X) | 0.69 | 0.58 | 1.20 | 0.95 | 0.82 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 6.32 | -40.54 | 10.29 | 11.05 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 6.19 | -47.02 | 9.91 | 10.58 |
| Earning Retention Ratio (%) | 0.00 | 93.68 | 140.54 | 89.71 | 88.95 |
| Cash Earning Retention Ratio (%) | 0.00 | 93.81 | 147.02 | 90.09 | 89.42 |
| Interest Coverage Ratio (X) | 10.26 | 18.02 | -1.06 | 11.44 | 15.81 |
| Interest Coverage Ratio (Post Tax) (X) | 7.37 | 14.43 | -2.03 | 8.80 | 13.86 |
| Enterprise Value (Cr.) | 121.71 | 85.03 | 30.51 | 39.19 | 32.72 |
| EV / Net Operating Revenue (X) | 3.44 | 2.61 | 8.11 | 1.69 | 1.70 |
| EV / EBITDA (X) | 5.83 | 3.10 | -25.50 | 2.06 | 2.18 |
| MarketCap / Net Operating Revenue (X) | 2.21 | 1.58 | 5.28 | 0.95 | 0.86 |
| Retention Ratios (%) | 0.00 | 93.67 | 140.54 | 89.70 | 88.94 |
| Price / BV (X) | 1.38 | 1.06 | 0.58 | 0.59 | 0.57 |
| Price / Net Operating Revenue (X) | 2.21 | 1.58 | 5.28 | 0.95 | 0.86 |
| EarningsYield | 0.11 | 0.30 | -0.12 | 0.43 | 0.54 |
After reviewing the key financial ratios for Elixir Capital Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.07. This value is within the healthy range. It has decreased from 26.89 (Mar 24) to 16.07, marking a decrease of 10.82.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.07. This value is within the healthy range. It has decreased from 26.89 (Mar 24) to 16.07, marking a decrease of 10.82.
- For Cash EPS (Rs.), as of Mar 25, the value is 22.64. This value is within the healthy range. It has decreased from 36.70 (Mar 24) to 22.64, marking a decrease of 14.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 97.83. It has decreased from 117.55 (Mar 24) to 97.83, marking a decrease of 19.72.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 97.83. It has decreased from 117.55 (Mar 24) to 97.83, marking a decrease of 19.72.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 60.94. It has increased from 56.07 (Mar 24) to 60.94, marking an increase of 4.87.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 35.96. This value is within the healthy range. It has decreased from 47.25 (Mar 24) to 35.96, marking a decrease of 11.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 35.10. This value is within the healthy range. It has decreased from 46.67 (Mar 24) to 35.10, marking a decrease of 11.57.
- For PBT / Share (Rs.), as of Mar 25, the value is 31.06. This value is within the healthy range. It has decreased from 44.94 (Mar 24) to 31.06, marking a decrease of 13.88.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 21.78. This value is within the healthy range. It has decreased from 36.11 (Mar 24) to 21.78, marking a decrease of 14.33.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 16.07. This value is within the healthy range. It has decreased from 26.89 (Mar 24) to 16.07, marking a decrease of 10.82.
- For PBDIT Margin (%), as of Mar 25, the value is 59.00. This value is within the healthy range. It has decreased from 84.27 (Mar 24) to 59.00, marking a decrease of 25.27.
- For PBIT Margin (%), as of Mar 25, the value is 57.60. This value exceeds the healthy maximum of 20. It has decreased from 83.23 (Mar 24) to 57.60, marking a decrease of 25.63.
- For PBT Margin (%), as of Mar 25, the value is 50.95. This value is within the healthy range. It has decreased from 80.14 (Mar 24) to 50.95, marking a decrease of 29.19.
- For Net Profit Margin (%), as of Mar 25, the value is 35.74. This value exceeds the healthy maximum of 10. It has decreased from 64.40 (Mar 24) to 35.74, marking a decrease of 28.66.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 26.37. This value exceeds the healthy maximum of 20. It has decreased from 47.96 (Mar 24) to 26.37, marking a decrease of 21.59.
- For Return on Networth / Equity (%), as of Mar 25, the value is 16.42. This value is within the healthy range. It has decreased from 32.22 (Mar 24) to 16.42, marking a decrease of 15.80.
- For Return on Capital Employeed (%), as of Mar 25, the value is 25.50. This value is within the healthy range. It has decreased from 39.68 (Mar 24) to 25.50, marking a decrease of 14.18.
- For Return On Assets (%), as of Mar 25, the value is 8.06. This value is within the healthy range. It has decreased from 16.19 (Mar 24) to 8.06, marking a decrease of 8.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.55. This value is within the healthy range. It has increased from 0.48 (Mar 24) to 0.55, marking an increase of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.33. It has decreased from 0.39 (Mar 24) to 0.33, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 2.35. This value is within the healthy range. It has decreased from 2.52 (Mar 24) to 2.35, marking a decrease of 0.17.
- For Quick Ratio (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has increased from 0.58 (Mar 24) to 0.69, marking an increase of 0.11.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 6.32 (Mar 24) to 0.00, marking a decrease of 6.32.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 6.19 (Mar 24) to 0.00, marking a decrease of 6.19.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 93.68 (Mar 24) to 0.00, marking a decrease of 93.68.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 93.81 (Mar 24) to 0.00, marking a decrease of 93.81.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 10.26. This value is within the healthy range. It has decreased from 18.02 (Mar 24) to 10.26, marking a decrease of 7.76.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.37. This value is within the healthy range. It has decreased from 14.43 (Mar 24) to 7.37, marking a decrease of 7.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 121.71. It has increased from 85.03 (Mar 24) to 121.71, marking an increase of 36.68.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.44. This value exceeds the healthy maximum of 3. It has increased from 2.61 (Mar 24) to 3.44, marking an increase of 0.83.
- For EV / EBITDA (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has increased from 3.10 (Mar 24) to 5.83, marking an increase of 2.73.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.21. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.21, marking an increase of 0.63.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 93.67 (Mar 24) to 0.00, marking a decrease of 93.67.
- For Price / BV (X), as of Mar 25, the value is 1.38. This value is within the healthy range. It has increased from 1.06 (Mar 24) to 1.38, marking an increase of 0.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.21. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.21, marking an increase of 0.63.
- For EarningsYield, as of Mar 25, the value is 0.11. This value is below the healthy minimum of 5. It has decreased from 0.30 (Mar 24) to 0.11, marking a decrease of 0.19.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Elixir Capital Ltd:
- Net Profit Margin: 35.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 25.5% (Industry Average ROCE: 21.7%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.42% (Industry Average ROE: 14.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.37
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 12.2 (Industry average Stock P/E: 137.3)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.55
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 35.74%
About the Company - Qualitative Analysis
Elixir Capital Ltd. is a Public Limited Listed company incorporated on 30/11/1994 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L67190MH1994PLC083361 and registration number is 083361. Currently Company is involved in the business activities of Activities auxiliary to financial service activities. Company's Total Operating Revenue is Rs. 0.75 Cr. and Equity Capital is Rs. 5.80 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Finance & Investments | 58, Mittal Chambers, Mumbai Maharashtra 400021 | cosec@elixirequities.com http://www.elixircapital.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dipan Mehta | Chairman |
| Mrs. Radhika Mehta | Whole Time Director |
| Mrs. Manori Shah | Independent Director |
| Mr. Shail Kapadia | Independent Director |
FAQ
What is the intrinsic value of Elixir Capital Ltd?
Elixir Capital Ltd's intrinsic value (as of 09 October 2025) is 173.53 which is 38.82% higher the current market price of 125.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹72.4 Cr. market cap, FY2025-2026 high/low of 351/101, reserves of ₹50.97 Cr, and liabilities of 115.59 Cr.
What is the Market Cap of Elixir Capital Ltd?
The Market Cap of Elixir Capital Ltd is 72.4 Cr..
What is the current Stock Price of Elixir Capital Ltd as on 09 October 2025?
The current stock price of Elixir Capital Ltd as on 09 October 2025 is 125.
What is the High / Low of Elixir Capital Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Elixir Capital Ltd stocks is 351/101.
What is the Stock P/E of Elixir Capital Ltd?
The Stock P/E of Elixir Capital Ltd is 12.2.
What is the Book Value of Elixir Capital Ltd?
The Book Value of Elixir Capital Ltd is 97.8.
What is the Dividend Yield of Elixir Capital Ltd?
The Dividend Yield of Elixir Capital Ltd is 1.00 %.
What is the ROCE of Elixir Capital Ltd?
The ROCE of Elixir Capital Ltd is 20.1 %.
What is the ROE of Elixir Capital Ltd?
The ROE of Elixir Capital Ltd is 18.0 %.
What is the Face Value of Elixir Capital Ltd?
The Face Value of Elixir Capital Ltd is 10.0.